Cue Biopharma, Inc.
CUEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. Valued at $135.6M, CUE is a micro-cap name in its sector. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Market Cap
$135.6M
Beta
2.63
P/E (TTM)
—
P/E (Fwd)
-38.88
EPS (TTM)
$-29.59
EPS (Fwd)
$-0.48
ROE
-1603.5%
ROA
-172.7%
Cash
$17.4M
Total Debt
$3.1M
Free CF
-$33.4M
52W Change
-20.8%
Annual Financials
Cash vs Debt
Where CUE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CUE finished 34.26% below its 150-day moving average ($24.46) and 22.58% below its 200-day moving average ($20.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CUE overbought or oversold?
At the October 20, 2026 close, CUE's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $17.4M in cash comfortably exceeding the $3.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$33.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1603.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.2M (2022) to $27.5M (2025), reflecting a 2106% increase over the period.
With a beta above 1.5, CUE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CUE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CUE.